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Abstract Analysis of liver safety data has to be multi-
variate by nature and needs to take into account time
dependency of observations. Current standard tools for
liver safety assessment such as summary tables, individual
data listings, and narratives address these requirements to a
limited extent only. Using graphics in the context of a
systematic workflow including predefined graph templates
is a valuable addition to standard instruments, helping to
ensure completeness of evaluation, and supporting both
hypothesis generation and testing. Employing graphical
workflows interactively allows analysis in a team-based
setting and facilitates identificatio\n of the most suitable
graphics for publishing and regulatory reporting. Another
important tool is statistical outlier detection, accounting for
the fact that for assessment of Drug-Induced Liver Injury,
identification and thorough evaluation of extreme values
has much more relevance than measures of central ten-
dency in the data. Taken together, systematical graphical
data exploration and statistical outlier detection may have
the potential to significantly improve assessment and
interpretation of clinical liver safety data. A workshop was
convened to discuss best practices for the assessment of
drug-induced liver injury (DILI) in clinical trials.
Key Points
In addition to standard summary tables and
narratives, graphics can help significantly to improve
liver safety assessment
A systematic workflow helps to ensure completeness
of evaluations and supports hypothesis generation
and testing
To differentiate true outliers from random variation,
robust statistical methods are available that should be
considered for liver safety evaluation
1 Introduction
Timely detection and proper assessment of drug-induced
liver injury (DILI) in clinical trials has for decades been
one of the key safety challenges for both pharmaceutical
industry and regulatory authorities.
A workshop was sponsored and organized jointly by the
European Innovative Medicines Initiative (IMI) and the
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Hamner Institute for Drug Safety Sciences (IDSS), with the
aim of addressing gaps in current guidance and initiating
alignment of liver safety assessment on a global scale.
On November 9, 2012, in Boston, regulatory experts
from the FDA, EMA, Health Canada, and the Japanese
National Institute of Health Sciences discussed with rep-
resentatives from industry and academia what could be
considered best practices in clinical liver safety assessment.
The best practices workshop focused on four key areas: 1)
data elements and data standards, 2) methodologies to
systematically analyze liver safety data, 3) tools and
methods for causality assessment, and 4) liver safety
assessment in special populations such as hepatitis and
oncology patients.
This section summarizes current methods for systematic
assessment of liver safety data, as discussed at the work-
shop, and provides respective recommendations for use in
clinical drug development.
Assessment of liver safety data needs to take into
account not only classic safety biomarkers such as standard
liver tests alanine aminotransferase (ALT), aspartate ami-
notransferase (AST), alkaline phosphatase (ALP), and total
bilirubin (TBIL), but also patient demographics, medical
history, adverse events and concomitant medication.
Moreover, time dependence of and covariation between
liver test results have to be factored in. Thus, proper
evaluation of liver safety profiles can be a highly complex
task, requiring comprehensive datasets and suitable ana-
lysis methods. Standard approaches such as use of tabular
summaries, narratives, and descriptive statistics may be
supplemented by graphical displays in a systematic work-
flow and outlier detection methods.
2 Tabular Summaries
2.1 Incidence Tables
Tabular summaries may be most useful to capture and
compare incidences of liver test elevations as well as
extent of changes from baseline across treatment groups
both at study and program level. In terms of incidences,
common thresholds to capture and assess liver test
related events are [3 9 ULN, [5 9 ULN, [10 9 ULN
for aminotransferase activities, and [2 9 ULN for bili-
rubin concentrations [1].
As for aminotransferase activities, both ALT and AST
are usually captured, although the added value of listing
AST in addition to ALT may be limited to helping with
differential diagnosis, i.e. differentiating muscle-related
from liver-related ALT elevations, as well as alcohol from
non-alcohol-associated etiology of liver test elevations [2,
3]. Addition of GGT, which seems to be more common in
Europe as compared to the US, may increase sensitivity for
cholestatic liver injury at the cost of decreasing specificity.
A general recommendation to either exclude or include
GGT measurements into the panel for liver safety assess-
ment cannot be given at this point in time [4].
2.2 Shift Tables
Shift tables listing number/percentage of patients shifting
e.g. from normal to above or below ULN while on treat-
ment as compared to baseline are widely used for safety
assessment in drug development. They provide a quick
overview on gross changes that might be treatment related.
However, a lot of valuable information may be lost by data
reduction using shift tables only. A more efficient approach
may be use of scatter plots displaying shifts from baseline
by study visit or maximum shifts from baseline during the
study, as outlined in Sect. 3.2.4.
2.3 Descriptive Statistics
Analyzing liver safety data often makes use of compar-
ing mean and/or median changes from baseline for liver
test results across treatments along with measures of
variability (standard deviation, standard error, and range).
Although this approach can add to understanding of drug
effects on the liver, it disregards the fact that predomi-
nant interest when assessing liver safety data will be on
outliers in the data. It is rather rare cases of idiosyncratic
DILI than more frequent dose-dependent intrinsic DILI
cases that give reason for concern and need thorough
data work-up, paying attention to all individual data as
well as trends in the overall dataset, association with
concomitant medication, medical history, and adverse
events.
Using graphics as an add-on to tabular summaries can
help to address these requirements and compensate for the
short-comings of the latter [5].
3 Graphical Workflows
Graphics, ideally in the setting of a defined, systematic
workflow using interactive graphics software, can take into
account the entirety of individual patient data as well as
trends across the population, and help paying attention to
the multivariate nature of safety signals and time depen-
dency of observations. A graphical workflow can help to
maximize knowledge gain from the data available, and at
the same time ensure completeness of safety evaluation. Of
great importance though is adhering to best practices for
graphical data exploration as outlined e.g. by Tukey and
Cleveland [6–8].
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3.1 Prerequisites
3.1.1 Normalization
Adequately assessing liver safety data needs comparison
between different continuous variables, across different
studies, different laboratories, etc. To facilitate that, nor-
malization is helpful. Simple normalization of dividing raw
liver test values by the Upper Limit of Normal (ULN)
values is used most often, although there are some limi-
tations associated with this approach. Even after normali-
zation, ULN corrected data may not be perfectly
comparable across different laboratories and the associated
variability might actually be misleading, possibly due to
the fact that the ‘‘standard’’ for calculating ULN is not
consistent. This has been illustrated using extensive Phase
II–IV clinical trial data from a generally healthy patient
population [9].
Normalization by individual baseline values may be a
better alternative when data have been generated across
different labs since it can reduce unnecessary variation
[10–12] and is more consistent across labs. However, given
that as yet there are only limited data available across
different populations on use of change from baseline as
compared to use of multiples of ULN, application of both
normalization approaches in parallel should be considered.
Graphs presented in this section are based on the as yet still
more common approach of multiples of ULN, but can
mostly be applied to baseline-corrected data as well. Using
multiples of baseline, scatter plots of shift from baseline as
presented in Sect. 3.2.4, however, could be replaced by
simple box plots across study visits and parameters.
In this context, attention needs to be given to definition
of baseline. As indicated in other sections of this paper,
taking just one measurement as an individual patient’s
baseline is not adequate, given within-subject variation of
liver tests [10, 12]. A more suitable determination of
baseline may consist of two measurements at least two
weeks but not more than two months apart. Data analysis
when at least two baseline measurements are available may
use minimum baseline to minimum post baseline and
maximum baseline to maximum post baseline changes to
account for within subject variation [13].
3.1.2 Data Types
Analyzing raw or normalized biomarker values only may
be insufficient to see the complete picture. Derived vari-
ables such as absolute and relative changes from baseline,
maximum values on treatment, flags for exceeding prede-
fined threshold values etc. may be required to adequately
interpret liver test results. Thus, before starting liver safety
data exploration, a set of derived variables should be
defined and calculated.
3.1.3 Data Structure
Typically, datasets for safety analysis include study iden-
tifier, subject identifier, visit numbers and visit names,
parameter names, parameter results, lower and upper limits
of normal ranges, units, and relevant covariates such as
age, gender, BMI, and ethnicity, displayed by column. For
most of the graphics used for liver safety exploration, this
structure is sufficient. However, in order to address specific
questions such as shape of bivariate distributions, shifts
from baseline by visit etc., transposing the dataset by
parameter names or by visits, i.e. having parameter names
or visit numbers as column headers may be necessary. In
order to support an efficient workflow, it is helpful to define
individual steps of the workflow and required data struc-
tures upfront and make sure analysis datasets are available
in all formats required.
3.1.4 Key Questions to be Addressed
Key questions to address when analyzing liver safety data
comprise:
• Are there any true Hy’s law cases in the dataset?
• How are changes across different liver tests correlated,
and how do those correlations differ between treatment
groups?
• What is the time dependent incidence of elevations of
liver tests in active treatment and comparator arms? Is
there a ‘‘window of susceptibility’’ in the active
treatment arm?
• Are shifts from baseline different between treatment
groups?
• Is there any evidence for a dose-response-relationship?
• What do time profiles of individual liver tests or liver
test panels look like?
• Are liver test changes observed during treatment
transient or progressing while a patient is on treatment?
• What do time profiles look like after treatment is
stopped?
• How does intake of certain concomitant medications or
occurrence and/or resolution of certain adverse events
relate to time profiles of liver tests?
• Are liver test elevations correlated with the desired
therapeutic effect of the drug?
• Are liver test elevations associated with non liver side
effects or laboratory abnormalities?
• Are liver test elevations associated with pharmacoki-
netic parameters of the drug (if available)?
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To systematically address these questions, a set of
standard graph templates can be used and customized as
required.
3.2 Graph Templates and Systematic Workflow
3.2.1 Correlations
Assessing correlations between liver tests, both absolute
values on treatment and changes from baseline, can provide
insight into underlying pathology of treatment associated
liver effects. Exploring relationships of liver test changes
with key covariates such as age, body mass index, gender,
ethnicity, may help to identify risk factors for DILI.
3.2.1.1 eDISH The key graphical representation to assess
a drug’s liver safety profile and to immediately identify
cases of special concern is the ‘‘eDISH’’ (evaluation of
Drug-Induced Serious Hepatotoxicity plot [14]), a log/log
display of correlation between peak TBIL vs. ALT, both in
multiples of ULN, with horizontal and vertical lines indi-
cating Hy’s law thresholds, i.e. ALT = 3 9 ULN and total
bilirubin = 2 9 ULN. The eDISH plot makes immediately
evident subjects potentially matching Hy’s law laboratory
criteria, all located in the upper right quadrant of the graph.
Data points in the lower right quadrant, i.e. exceeding 3 9
ULN for ALT, but being below 2 9 ULN for total biliru-
bin, suggest an increased risk for liver injury as well, if
incidence is differing between active treatment and control
groups, however, not to the same extent and with less
specificity as compared to Hy’s law.
Figure 1 shows an example of an eDISH plot, compar-
ing pooled study drug against control data. Horizontal and
vertical lines indicate Hy’s law thresholds.
Patients with active treatment show a higher incidence
of values in the lower right quadrant and twelve potential
Hy’s law cases in the upper right quadrant, thus suggesting
a potential risk for severe drug-induced liver injury asso-
ciated with this drug. As stated in the FDA’s guidance on
Drug-Induced Liver Injury, ‘‘…Finding one Hy’s Law case
in the clinical trial database is worrisome; finding two is
considered highly predictive that the drug has the potential
to cause severe DILI when given to a larger population.’’
[1].
A limitation with the standard eDISH plot is its lack of
displaying sequence of maximum observed values for ALT
and bilirubin, i.e. which of both was first, as well as length
of time intervals between maximum observed values.
However, from a clinical perspective, these data are highly
relevant, since only bilirubin elevations simultaneous with
or soon following peak ALT elevations may indicate loss
of hepatic function due to liver injury. Moreover, a long
time interval, exceeding four weeks, between both peaks
may also speak against a causal correlation.
Another limitation of the standard eDISH plot is its lack
of displaying levels of ALP at the time of peak ALT ele-
vation. Elevation of ALP[2 9 ULN or a ratio R ([ALT 9
ULN]/[ALP 9 ULN]) \5 preceding or simultaneous with
Fig. 1 eDISH plot, TBIL [9 ULN] vs. ALT [9 ULN] on a log/log scale, treatment by panel, pooled active versus control. ULN upper limit of
normal, ALT alanine aminotransferase, TBIL total bilirubin
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ALT elevations suggests cholestatic/mixed type liver dis-
ease, such that cases of combined bilirubin and ALT ele-
vations would not qualify as Hy’s law cases.
It is desirable to have all this information included in the
graphical display, as well. Figure 2 shows the same data as
above, using a proposed modification to the eDISH plot,
with color coding for sequences of ALT and bilirubin
peaks, and size coding for the time interval between both
peaks. In order to make the most relevant data points easily
visible, the more concerning sequence of bilirubin parallel
to or following ALT peak is coded in red, the time interval
is coded as 1/interval to make shorter time intervals being
displayed as larger markers. Filled circles refer to data
having R [5. Thus, the data points to watch out for,
qualifying as potential Hy’s law cases, primarily are large,
filled, red circles in the upper right quadrant.
In the above example, nine of the twelve data points in
the Hy’s law quadrant for patients in active treatment
groups show the sequence of interest, i.e. bilirubin fol-
lowing or simultaneously elevated with ALT peak, but only
one of those has a time interval of less than four weeks
between both peaks and R [5. Thus, using this modified
version of the eDISH plot, eleven out of twelve potential
Hy’s law cases can be immediately identified as being
likely less relevant.
However, given that the eDISH plot is using peak values
only, even for patients displaying a likely less relevant data
point in the modified eDISH plot there may be other
measurements during a trial not being peak values, but
meeting Hy’s law criteria, having the proper sequence of
events, i.e. TBIL following ALT within a short period of
time, plus an R[5. Those data could be ‘‘masked’’ by less
relevant peak values and hence not be displayed in the
eDISH plot. Thus, it needs to be underlined that, using a
modified eDISH plot as outlined above, with color, shape
and size coding to identify the likely more relevant cases,
can only aid prioritization of cases but not replace thor-
ough evaluation of all patients displayed in the Hy’s law
quadrant.
Another useful modification of eDISH takes into
account changes from baseline instead of absolute values
for TBIL and ALT, along with population specific thresh-
olds, as suggested by Lin et al. [15] which is described in
more detail in Sect. 4.1.1.
3.2.1.2 Other Correlations Other correlations of interest
when exploring liver safety profiles of new drugs are those
between different liver enzymes, i.e. ALT/AST, ALT/GGT,
and ALT/ALP. Whereas in the healthy liver, ALT and AST
are closely correlated, ALT and the two other enzymes
usually are not. However, in some cases of DILI, elevations
of ALP and/or GGT may correlate with increased ALT
activities, providing some hints about the underlying
pathology, i.e. cholestasis or mixed type cholestatic/hepa-
tocellular injury. Isolated elevations of GGT activities
without associated ALT or ALP changes may sometimes
indicate enzyme induction rather than cell injury, as
observed e.g. in cases of chronic alcohol abuse [16].
3.2.2 Time Profiles
Changes of liver tests over time can provide crucial
information on both underlying pathology and causal
relationship to drug treatment. Line plots of either
Fig. 2 Modified eDISH plot, color by sequence of peak values, size by 1/time interval between peaks, shape by R flag. ULN upper limit of
normal, ALT alanine aminotransferase, TBIL total bilirubin, BIL bilirubin
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individual markers or marker panels are most useful to
assess biomarker time profiles, particularly if combined
with elements indicating start and/or end of drug treatment,
dose levels etc. In the context of a systematic workflow
using interactive graphics software, evaluation of time
profiles ideally follows assessment of the eDISH plot via
drill-down from selected data points, e.g. points in the Hy’s
law quadrant.
Figure 3 provides an overview on liver test profiles over
time for 19 patients in a clinical study who showed ALT
elevations [3 9 ULN while on treatment, one panel per
patient. Treatment end is indicated by a vertical red line,
color coding is by liver test, horizontal lines represent ULN
(green line) and 3 9 ULN (red line), respectively.
As displayed in the plot, several patients showed short-
lived, transient peaks of ALT, with serum activities
decreasing despite continued treatment. Only few patients
had to be taken off treatment due to continuous or wors-
ening elevations of ALT.
Moreover, the plot allows assessing time-wise associa-
tion of different biomarker effects by patient. Only patient
0004_00016 shows discrete elevation of ALP in parallel
with peak ALT and AST, pointing towards a possible
cholestatic component of liver injury. There are no
apparent elevations of bilirubin parallel or subsequent to
ALT elevations in any of the patients, confirming the rather
benign nature of liver enzyme changes observed in the
study.
3.2.3 Association with Concomitant Medication
and Adverse Events
A particularly helpful graph to analyze association of liver
test changes with adverse events and concomitant medi-
cation is a patient profile, defined as synoptic presentation
of line plots for all three items along a shared time axis.
Figure 4 displays for an individual patient the ALT
profile over time on top of the plot, concomitant medica-
tion and adverse events beneath. The horizontal red line in
the top plot represents 3 9 ULN for ALT. In the two lower
plots, start and end times of concomitant medication intake
and adverse events are displayed as blue triangles, the
black line between associated triangles indicates ongoing
concomitant medication or adverse event, respectively.
As displayed in the plot, the patient had taken an acet-
aminophen-containing medication, NyquilTM, and an
Fig. 3 Time profiles of ALT, AST, ALP, and TBIL, panel by patients, treatment end indicated by vertical red line, ULN and 3 9 ULN indicated
by horizontal green and red line, respectively. Color coding by liver test. ALT alanine aminotransferase, AST aspartate aminotransferase, ALP
alkaline phosphatase, TBIL total bilirubin, ULN upper limit of normal
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ibuprofen-containing medication, AdvilTM, before the first
ALT peak, and again AdvilTM, around the time of the
second ALT peak. Both drugs might have been causally
related to the ALT elevation. Moreover, the patient
reported several adverse events of headache during the
trial, one particularly preceding the second ALT peak. It is
conceivable that the patient might have taken e.g. acet-
aminophen to treat his headache but forgotten to report this
as concomitant medication.
Observing this kind of temporal association of ALT
peaks with headache or other pain events in a graphical
display can trigger focused re-questioning the patient to
ensure no suspicious comedication has been used around
the time of liver enzyme elevation.
Thus, a synoptic display of ALT profiles, concomitant
medication and adverse events may sometimes help sub-
stantially to identify causes for clinically relevant changes
in liver safety biomarkers.
3.2.4 Shifts from Baseline
Liver test results always have to be viewed in the context of
their respective baselines to allow adequate assessment of
treatment or disease effects. This can be done either by
analyzing absolute and relative changes from baseline, or
by using scatter plots with baselines on the x-axis and e.g.
maximum post-baseline values on the y axis. When plot-
ting only maximum post-baseline values on the y-axis,
however, careful consideration needs to be given to the
number of post-baseline measurements per patient, partic-
ularly when no control groups are available for comparison
across treatments: the larger the number of post-baseline
observations per patient, the more biased the plot will be
towards values increasing from baseline. To avoid that, an
alternative is e.g. to plot all post-baseline values per
patient, instead of selecting the maximum values only, or
displaying shifts as scatter plots by visit.
Figure 5 shows a respective example with four post-
baseline observations per patient. This is a Trellis plot with
treatment groups across rows and biomarker names across
columns. Color coding is by gender. The blue diagonal line
in each panel represents the line of identity, i.e. each value
on the line corresponds to maximum post-baseline equaling
baseline, each point above the line is an increase, points
below the line are a decrease from baseline, respectively.
In addition, the plot allows to assess the number of
patients exceeding certain threshold values, represented by
the green (=ULN) and red (3 9 ULN) horizontal and
vertical broken lines in each panel.
In this example, there is a clear trend for higher shifts
from baseline, i.e. elevations, for ALT and AST in both
active treatment groups. However, even the placebo
group displays some elevations from baseline at least for
ALT. Although this is a phenomenon not uncommon in
clinical studies and may be explained by effects of diet,
physical exercise, concomitant disease or comedication,
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Fig. 5 Shifts from baseline, parameters by column, treatment groups by row, color coding by gender. ULN upper limit of normal, max
maximum, max post bsl maximum post baseline
Fig. 6 Shifts from baseline, visits by column, treatment by rows, color coding by parameter. ALT alanine aminotransferase, TBIL total bilirubin,
ULN upper limit of normal, post bsl post baseline
S40 M. Merz et al.
the effect may at least partially also be due to a bias
introduced by the number of post-baseline measurements,
as outlined above.
Figure 6 shows an example displaying shifts by visit,
avoiding the bias by multiple measurements when plotting
only maximum post-baseline values.
3.2.5 Dose-Response-Relationship
In order to assess dose effects more quantitatively than feasible
via scatter plots, box plots may be used for absolute or relative
changes from baseline and compared across treatment groups.
Figure 7 shows maximum absolute changes from baseline per
Fig. 7 Maximum absolute changes from baseline across treatment groups, parameters by panel, treatment groups by column per panel
Fig. 8 Kaplan–Meier plot of incidence of ALT elevations over time across treatment groups. ALT alanine aminotransferase
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patient for liver enzymes across treatment groups. Plots per
treatment group are defined by median (white line), lower and
upper quartiles (box), lower and upper adjacent values (whis-
kers), and outliers (individual data points). Outliers are jittered
on the x-axis to improve visibility.
The plot suggests differences for maximum elevations
from baseline of ALT and AST as compared between both
active treatment groups and placebo treatment.
For ALP, only a potential trend towards higher elevations
with active treatment as compared to placebo can be observed.
3.2.6 Kaplan–Meier Plots
Capturing and comparing time to elevation of liver test
results across treatment groups is of key importance not only
for understanding and adequately interpreting a potential
liver safety signal but also for managing the risk associated
with any effects of the study drug on the liver, e.g. in terms of
defining adequate monitoring intervals. The graphical dis-
play most widely used to show and compare times to event is
the Kaplan–Meier plot, which, in the absence of truncation,
censoring, and competing risks corresponds to the empirical
cumulative distribution function of incidences to reach a
predefined threshold. Such plots can sometimes reveal clear
active treatment effects on serum ALT not evident from
aggregate data, especially if the active drug treated diseases
associated with ALT elevations (e.g. diabetes, congestive
heart failure and viral hepatitis).
Figure 8 shows an example of ALT elevations[3 9 ULN
for drug X (blue line) as compared to control (red line).
4 Other Methods
4.1 Outlier Detection
Particularly for idiosyncratic DILI, identification of
abnormal liver chemistry data may be considered as an
outlier detection problem. An outlier refers to an obser-
vation that deviates markedly from the pattern or dis-
tribution of the majority of the data. Graphical displays
such as the eDISH plot, shift plots, or box plots, as
outlined above, can help substantially to spot clinically
relevant outliers in clinical trial data, but sometimes have
limited value in terms of reliably differentiate true out-
liers from random variation. To facilitate that, various
robust statistical methods have been proposed, as
described in more detail for instance in [15, 17–20]. The
following section describes for consideration an approach
that has been applied to liver safety data and makes use
of both ULN- and baseline-normalized data.
4.1.1 Truncated Robust Multivariate Outlier Detection
(TRMOD)
Multivariate outlier detection based on a robust distance
measure has been studied extensively and applied to detect
outliers in multivariate laboratory data [21]. Mahalanobis
distance measures the distance of a subject from the center
of the multivariate normal distribution. Multivariate outli-
ers are usually detected based on robust distance which
uses the robust estimate of mean and covariance in the
calculation of Mahalanobis Distance [17]. The decision
boundary for multivariate outlier detection based on a
multivariate normal distribution has an ellipsoidal shape in
general [19] and is an ellipse for the bivariate (two mark-
ers) case (Fig. 9a). The ellipse is a good graphical indicator
of the correlation between two variables. The ellipse col-
lapses diagonally as the correlation between the two vari-
ables approaches either 1 or -1. The ellipsoid is more
circular (less diagonally oriented) if the two variables are
less correlated.
Multivariate outliers detected based on such decision
boundaries will include outliers in all directions. However,
only abnormally high elevations of liver chemistry mea-
surements ALT, AST, ALP, and TBIL indicate a potential
Fig. 9 a TRMOD boundary
for two correlated
measurements. b TRMOD
boundary for ALT and bilirubin
with four regions: (Region I)
severe toxicity or potential Hy’s
Law, (Region II) elevated
bilirubin, (Region III) elevated
ALT, and (Region IV)
potentially toxicity. ALT alanine
aminotransferase
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liver safety issue. Hence, outliers with abnormally small
values of these liver chemistries are not of interest in
identifying potential liver toxicity and would be considered
clinically irrelevant outliers. TRMOD [15] was proposed as
a robust statistical method for identification of clinically
relevant outliers in laboratory safety data while automati-
cally excluding clinically irrelevant outliers. The decision
boundary defined by the truncated robust distance is shown
in Fig. 9a as a solid line [15]. The TRMOD boundaries are
determined based on robust estimates of mean and
covariance from the data and can be adjusted based on a
specified false detection probability value. In applying
TRMOD to liver chemistry data, log transformation of
ALT and bilirubin is used so that the majority of the data
can be modeled approximately as a multivariate normal
distribution. The two liver chemistry measurements, ALT
and bilirubin, are not highly correlated, and the decision
boundary then appears rounded similar to Fig. 9b.
Truncation lines in TRMOD, i.e. x-limit and y-limit, are
determined by their intersection with the horizontal and
vertical axis. X-limit and y-limit can be used for compar-
ison with other thresholds based on methods such as
eDISH. By extending the truncation line as given in
Fig. 9b, using TRMOD it is possible to achieve decision
boundaries very similar to eDISH. For the two liver
chemistry measurements ALT-limit is interpreted as the
x-limit and bilirubin limit as the y-limit. ALT and bilirubin
data can be either ULN-corrected or baseline corrected.
ALT and bilirubin limits define regions similar to eDISH.
Together, they form regions identified as: (Region I) severe
toxicity or potential Hy’s Law, (Region II) elevated bili-
rubin, (Region III) elevated ALT, and (Region IV) poten-
tial toxicity. Outliers lying in region IV, based on the
multivariate analysis, may indicate some abnormality in
both ALT and bilirubin simultaneously, requiring further
attention. In fact, ignoring region IV, the shape of the
decision boundaries are exactly the same in both TRMOD
and eDISH. An important difference, however, is that the
TRMOD boundaries are estimated from data, in compari-
son to the eDISH boundaries which are fixed since they
were derived from Hy’s Law. Since TRMOD based deci-
sion boundaries are derived from data and are comparable
to eDISH limits for liver chemistry data, it has been sug-
gested to name the associated plot ‘‘modified eDISH’’,
‘‘mDISH’’.
4.1.1.1 Hy’s Law Examined by TRMOD In order to
compare TRMOD boundaries to empirically derived and
fixed thresholds of FDA’s Hy’s Law limits, data from 28
Phase II–IV clinical trials performed at GSK were aggre-
gated and analyzed by the TRMOD algorithm. ALT and
total bilirubin data were analyzed and assessed graphically
with the FDA’s evaluation of Drug Induced Serious Hep-
atotoxicity (eDISH) plot assessing fold-ULN, as well as
using a modified eDISH (mDISH) plot to assess fold-
baseline liver chemistries [22]. The data consisted of
18,672 predominantly female subjects with mean age of
44 years and without known liver disease.
Among generally healthy clinical trial subjects,
the empirically derived TRMOD boundaries were
Fig. 10 a Hy’s Law and eDISH Plot on ULN corrected data: ALT [3 9 ULN and total bilirubin [2 9 ULN; b TRMOD boundaries and
mDISH plot on ULN corrected data: ALT[3.4 9 ULN and bilirubin[2.1 9 ULN. ALT alanine aminotransferase, ULN upper limits of normal
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approximately equivalent to ‘Hy’s Law.’ In comparison to
FDA’s ‘Hy’s Law’ boundaries of 3 9 ULN and bilirubin 2
9 ULN (Fig. 10a), TRMOD identified outliers with ALT
limit of 3.4 9 ULN and bilirubin limit of 2.1 9 ULN
(Fig. 10b). In order to minimize confounding by inter-
laboratory variation across the 28 studies, baseline cor-
rected data were used in addition. By applying TRMOD to
baseline corrected data, boundaries were 3.8 9 baseline for
ALT and 4.8 9 baseline for bilirubin (Fig. 11).
Overall, TRMOD liver chemistry analyses of clinical
trial data in generally healthy subjects confirmed the
FDA’s Hy’s Law threshold as a robust means to detect
liver safety outliers. TRMOD evaluation of liver chemistry
data, by both fold-ULN and fold-baseline, provides a
complementary analysis method and can generate valuable
data to establish evidence-based decision boundaries across
patient populations. Use of baseline corrected data reduces
impact of inter-laboratory variation and may be more
sensitive to possible drug effects. However, more data is
needed to confirm its value. As long as that data is not
available, it is proposed to assess liver chemistries using
graphical depictions of both ULN corrected data (eDISH)
and modified eDISH (mDISH) for baseline corrected data,
as complementary methods.
TRMOD methodology has also been applied to liver
chemistry data from 31 aggregated GSK oncology clinical
trials to establish population-based thresholds for assess-
ment of liver injury [23]. TRMOD identified outliers with
an ALT limit 5.0 9 ULN and total bilirubin limit 2.7 9
ULN. Additionally, TRMOD was applied to the aggregated
oncology data to examine fold-baseline ALT and total
bilirubin, indicating outlier detection limits of ALT 6.9 9
baseline and bilirubin 6.5 9 baseline [23]. Thus, bound-
aries for outlier detection based on TRMOD methodology
were wider in the oncology population as compared to
healthy subjects. Similar ALT and bilirubin threshold
limits were observed for oncology patients both with and
without liver metastases.
4.1.2 Univariate and Multivariate Extreme Value
Modelling
A slightly different approach to outlier detection has been
suggested by Southworth and Heffernan [18, 20] based on
extreme value theory. The method estimates probabilities
of exceeding thresholds of concern, e.g. ALT [3 9 ULN
and TBIL [2 9 ULN, fitting a generalized Pareto distri-
bution (GPD) to marginal data values above an appropri-
ately chosen threshold, where the effect of baseline on
post-treatment values is eliminated by robust regression
modelling. Model based probabilities for liver tests
exceeding predefined thresholds can support identification
of potential liver safety signals even with rather small
sample sizes, e.g. predicting incidence and magnitude of
outliers in phase III studies or post marketing based on
phase II data.
5 Conclusions and Recommendations
Liver safety data from clinical trials usually is complex,
multivariate by nature, and typically includes multiple
measurements over time. Association of biomarker effects
with clinical adverse events, concomitant diseases, and
concomitant medication needs to be accounted for.
• In addition to standard summary tables and narratives,
graphics can help significantly to detect signals,
understand cause–effect relationships, assess mecha-
nisms of toxicity, and may support both risk evaluation
and management.
• To facilitate assessment and comparison of liver tests
across different parameters, labs, and studies, normal-
ization of data is required. The most common approach
of normalizing values by lab-specific upper limits of
normal may be supplemented by normalization using
the patient’s baseline values.
• Proper definition of baseline needs to take into account
more than one measurement prior to study treatment.
Two measurements at least two weeks apart may be
considered a suitable definition.
• A systematic workflow, including predefined graphical
templates, starting from the eDISH plot and including a
series of line plots, scatter plots, box-plots, and Kaplan–
Meier plots helps to ensure completeness of evalua-
tions, supports hypothesis generation and testing, and
facilitates identification of the most suitable graphics
for publishing and regulatory reporting.
Fig. 11 TRMOD boundaries and mDISH plot on baseline corrected
data: ALT [3.8 9 baseline and bilirubin [4.8 9 baseline. ALT
alanine aminotransferase
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• In particular for detection and assessment of idiosyn-
cratic DILI, attention needs to be given to outliers in a
dataset rather than just mean and median values of liver
tests. To differentiate true outliers from random vari-
ation, robust statistical methods are available that
should be considered for liver safety evaluation.
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